Former President Saliya Pieris PC yesterday hailed the historic victory of National People’s Power (NPP) at Thursday’s ...

BOSTON (AP) — BOSTON (AP) — Pieris Pharmaceuticals Inc. (PIRS) on Wednesday reported a loss of $2.9 million in its third quarter. On a per-share basis, the Boston-based company said it had a loss of ...

Recently and prior to F-Star, she worked in CFO roles across numerous biotech and pharmaceutical companies, including ...

Paulus Edward Pieris Deraniyagala was a Sri Lankan paleontologist, zoologist and archaeologist. He made several contributions ...

Pieris Pharmaceuticals’ long-standing immuno-oncology alliance with Servier is being dissolved after a clinical trial of the lead drug in the alliance revealed a safety concern. In a Securities ...

The ASPI closed in green as a result of price gains in counters such as John Keells Holdings, Richard Pieris & Company and C ...

Researchers are exploring how small airway abnormalities in younger smokers could help identify who is at risk of developing COPD and establish how the chronic lung disease progresses.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Colombo stock market yesterday apparently revved up for tomorrow’s Parliamentary Election with the benchmark ASPI momentarily touching 13,000-points mark and turnover crossing Rs. 4 billion.

Dr. Bruns previously served as the Senior Vice President and Head of Clinical Development at Pieris Pharmaceuticals, a publicly traded clinical stage biotechnology company, where he built and led the ...

Additionally, he has served on the boards of HNB subsidiary, Sithma Development (Pvt) Ltd. and Associate, Splender Media (Pvt) Ltd., and as an independent Director at Richard Pieris Finance Ltd., ...

Opus Genetics Inc (IRD) is expected to report $-0.33 for 3Q. Passage Bio Inc (PASG) is expected to report $-0.23 for 3Q. Pieris Pharmaceuticals Inc (PIRS) is expected to report for 3Q. Reliv ...